Drug Type Small molecule drug |
Synonyms Hengmu, 艾美酚胺替诺福韦, HS 10234 + [4] |
Target |
Mechanism RT inhibitors(Reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (24 Jun 2021), |
RegulationPriority Review (CN), Special Review Project (CN) |
Molecular FormulaC26H35N6O9P |
InChIKeyFTBUYHOGDVLBTE-PHAALIGXSA-N |
CAS Registry1571076-41-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis B, Chronic | CN | 24 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 1 | CN | 03 Aug 2020 |
Phase 3 | 1,002 | jiqmtmmzph(wtzmykpxwl) = umjpvjaqjr ircfthllty (dppmoumzfg ) View more | Non-inferior | 01 Nov 2021 | |||
jiqmtmmzph(wtzmykpxwl) = rlzvydvfim ircfthllty (dppmoumzfg ) View more | |||||||
Phase 1 | - | 36 | mfdqbfkrds(lzewppfzod) = ujgxxtneyr huefernfgh (mmoqgwharx ) View more | - | 30 Oct 2021 | ||
mfdqbfkrds(lzewppfzod) = hhlrlgodpk huefernfgh (mmoqgwharx ) View more |